Analysts Set Dianthus Therapeutics, Inc. (NASDAQ:DNTH) PT at $60.88

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) have earned an average rating of “Moderate Buy” from the eleven ratings firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and ten have issued a buy recommendation on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $60.8750.

Several equities analysts have recently commented on the stock. Stifel Nicolaus upped their price target on shares of Dianthus Therapeutics from $52.00 to $65.00 and gave the stock a “buy” rating in a research report on Friday, September 12th. Raymond James Financial reiterated an “outperform” rating and issued a $63.00 target price (up previously from $56.00) on shares of Dianthus Therapeutics in a research report on Tuesday, September 9th. Truist Financial initiated coverage on shares of Dianthus Therapeutics in a research report on Tuesday, October 14th. They issued a “buy” rating and a $56.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Wednesday, October 8th. Finally, Guggenheim increased their target price on shares of Dianthus Therapeutics from $92.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, September 9th.

Insider Transactions at Dianthus Therapeutics

In related news, CFO Ryan Savitz sold 20,000 shares of the stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $35.00, for a total value of $700,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 16.56% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Dianthus Therapeutics

Large investors have recently made changes to their positions in the business. Raymond James Financial Inc. bought a new position in shares of Dianthus Therapeutics during the 2nd quarter valued at about $27,000. US Bancorp DE boosted its position in shares of Dianthus Therapeutics by 2,013.3% during the 1st quarter. US Bancorp DE now owns 1,585 shares of the company’s stock valued at $29,000 after purchasing an additional 1,510 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Dianthus Therapeutics by 3,030.6% during the 1st quarter. GAMMA Investing LLC now owns 3,882 shares of the company’s stock valued at $70,000 after purchasing an additional 3,758 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Dianthus Therapeutics by 330.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock valued at $80,000 after purchasing an additional 3,317 shares in the last quarter. Finally, AlphaQuest LLC bought a new position in shares of Dianthus Therapeutics during the 2nd quarter valued at about $94,000. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Stock Performance

Dianthus Therapeutics stock opened at $33.52 on Thursday. The company has a 50-day simple moving average of $32.74 and a 200-day simple moving average of $24.12. The firm has a market capitalization of $1.08 billion, a P/E ratio of -10.31 and a beta of 1.58. Dianthus Therapeutics has a one year low of $13.36 and a one year high of $40.16.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.02). The firm had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.87 million. Dianthus Therapeutics had a negative return on equity of 34.72% and a negative net margin of 2,364.56%. As a group, sell-side analysts forecast that Dianthus Therapeutics will post -2.61 earnings per share for the current year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.